Poziotinib (HM781-36B) | EGFR Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1092364-38-9
Formula :	C₂₃H₂₁Cl₂FN₄O₃
M.W :	491.34
SMILES Code :	C=CC(N1CCC(OC2=CC3=C(NC4=CC=C(Cl)C(Cl)=C4F)N=CN=C3C=C2OC)CC1)=O
Synonyms :	HM781-36B; NOV120101
MDL No. :	MFCD28044290
InChI Key :	LPFWVDIFUFFKJU-UHFFFAOYSA-N
Pubchem ID :	25127713

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

A2780-SP cells	20 nM	6 days	Inhibited ovarian cancer stem cell sphere formation and viability, induced apoptosis	PMC7583017
SKOV3-SP cells	10 nM	6 days	Inhibited ovarian cancer stem cell sphere formation and viability, induced apoptosis	PMC7583017
MM134 HER2 L755S cells	10 mM	4 hours	To evaluate the inhibitory effect of poziotinib on downstream signaling in HER2 L755S cells, results showed that poziotinib significantly inhibited the expression of pHER2 and p-Akt.	PMC9379360
MCF7 L755S KI cells	10 mM	4 weeks	To evaluate the growth inhibitory effect of poziotinib on MCF7 L755S KI cells, results showed that poziotinib significantly inhibited cell growth.	PMC9379360
Ba/F3 cells	1.0 nM	72 hours	Poziotinib potently inhibited Ba/F3 cells with EGFR exon 20 mutations, with an IC50 value of 1.0 nM	PMC5964608
Ba/F3 cells	1.9 nM	72 hours	Poziotinib potently inhibited Ba/F3 cells with HER2 exon 20 mutations, with an IC50 value of 1.9 nM	PMC5964608
H1781 cells	7.7 nM	72 hours	Poziotinib potently inhibited H1781 cells, with an IC50 value of 7.7 nM	PMC5964608
CUTO14 cells	1.84 nM	72 hours	Poziotinib potently inhibited CUTO14 cells, with an IC50 value of 1.84 nM	PMC5964608
YUL-0019 cells	0.30 nM	72 hours	Poziotinib potently inhibited YUL-0019 cells, with an IC50 value of 0.30 nM	PMC5964608
SKOV3-SP cells	10 nM	6 days	Evaluate the effect of Manidipine alone or in combination with Poziotinib on the spheroid growth and viability of ovarian cancer stem cells. Results showed that combination treatment more effectively inhibited sphere size and viability than Manidipine alone.	PMC7583017
A2780-SP cells	20 nM	6 days	Evaluate the effect of Manidipine alone or in combination with Poziotinib on the spheroid growth and viability of ovarian cancer stem cells. Results showed that combination treatment more effectively inhibited sphere size and viability than Manidipine alone.	PMC7583017
SKOV3 cells	10 nM	6 days	Evaluate the effect of Manidipine alone or in combination with Poziotinib on the spheroid growth and viability of ovarian cancer stem cells. Results showed that combination treatment more effectively inhibited sphere size and viability than Manidipine alone.	PMC7583017
A2780 cells	20 nM	6 days	Evaluate the effect of Manidipine alone or in combination with Poziotinib on the spheroid growth and viability of ovarian cancer stem cells. Results showed that combination treatment more effectively inhibited sphere size and viability than Manidipine alone.	PMC7583017

Mice	MM134 HER2 L755S MIND xenograft model	Oral	10 mg/kg	Once a week for 7 weeks	To evaluate the inhibitory effect of poziotinib on tumor growth and metastasis in the MM134 HER2 L755S MIND xenograft model, results showed that poziotinib significantly inhibited tumor growth and metastasis.	PMC9379360
Mice	EGFR D770insNPG genetically engineered mouse model	Oral	10 mg/kg	daily for 4 weeks	Poziotinib significantly reduced tumor volume by 80% in GEMMs with an EGFR exon 20 mutation	PMC5964608

{[proInfo.proName]}

CAS No.: 1092364-38-9

{[proInfo.proName]}

CAS No.: 1092364-38-9

Alternative Products

Product Details of Poziotinib

Safety of Poziotinib

Related Pathways of Poziotinib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03066206	EGFR Exon 20 Mutation\|ERBB2 Ge... More >>ne Mutation\|Recurrent Lung Non-Small Cell Carcinoma\|Stage IV Non-Small Cell Lung Cancer AJCC v7 Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2025-12-31	M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less <<
NCT02216916	HNSCC	PHASE2	UNKNOWN	2025-07-19	Yonsei University, Seoul, Kore... More >>a, Republic of Less <<
NCT02544997	Metastatic Breast Cancer	PHASE2	COMPLETED	2025-02-20	Samsung Medical Center, Seoul,... More >> 135-710, Korea, Republic of Less <<
NCT02979821	HER2 Gene Mutation\|Adenocarcin... More >>oma Lung Stage IV Less <<	PHASE2	COMPLETED	2025-12-17	Korean Association for the Stu... More >>dy of Targeted Therapy, Seoul, Korea, Republic of Less <<
NCT04044170	NSCLC	PHASE2	TERMINATED	2020-04-13	Beijing Cancer Hospital, Beiji... More >>ng, China\|Beijing Chest Hospital, Beijing, China\|Beijing Hospital, Beijing, China\|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China\|Peking Union Medical College Hospital, Beijing, China\|Jilin Cancer Hospital, Changchun, China\|The First Hospital of Jilin University, Changchun, China\|The Third Xiangya Hospital of Central South University, Changsha, China\|Sichuan Cancer Hospital and Institute, Chengdu, China\|West China Hospital of Sichuan University, Chengdu, China\|Fujian Provincial Cancer Hospital, Fuzhou, China\|Guangdong General Hospital, Guangzhou, China\|Guangdong Panyu Central Hospital, Guangzhou, China\|Shi Run Run Shaw Hospital, Zhejiang University, Hangzhou, China\|The First Affiliated Hospital, Zhejiang University, Hangzhou, China\|Zhejiang Cancer Hospital, Hangzhou, China\|The Second Hospital of Anhui Medical University, Hefei, China\|Shanghai Chest Hospital, Shanghai, China\|University of Hong Kong-Shenzhen Hospital, Shenzhen, China\|Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China\|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China\|Chungbuk National University Hospital, Cheongju, Korea, Republic of\|National Cancer Center, Gyeonggi-do, Korea, Republic of\|Asan Medical Center, Seoul, Korea, Republic of\|Samsung Medical Center, Seoul, Korea, Republic of\|Seoul National University Hospital, Seoul, Korea, Republic of Less <<
NCT03318939	NSCLC	PHASE2	TERMINATED	2023-04-03	Mayo Clinic Hospital, Phoenix,... More >> Arizona, 85054, United States\|Oncology Physician's Network Inc./OPN Healthcare, Arcadia, California, 91007, United States\|City of Hope, Duarte, California, 91010, United States\|UCSD -Moores Cancer Center, La Jolla, California, 92093, United States\|Pacific Shores Medical Group, Long Beach, California, 90813, United States\|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, 90017, United States\|USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States\|UC Davis Comprehensive Cancer Center, Sacramento, California, 95817, United States\|UCSF Helen Diller Comprehensive Cancer Center at Mt Zion, San Francisco, California, 94115, United States\|UCLA Hematology/Oncology, Santa Monica, California, 90404, United States\|The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, 90502, United States\|Kaiser Permanente Medical Center, Vallejo, California, 94589, United States\|Rocky Mountain Cancer Center, Boulder, Colorado, 80303, United States\|Yale University, Yale Cancer Center Smilow Cancer Hospital at Yale, New Haven, Connecticut, 06510, United States\|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States\|Florida Hospital, Orlando, Florida, 32804, United States\|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States\|The Bond & Steele Clinic, P.A. dba Bond Clinic, P.A., Winter Haven, Florida, 33881, United States\|University Cancer & Blood Center, LLC, Athens, Georgia, 30607, United States\|CTCA - Southeastern Regional Medical Center, Newnan, Georgia, 30265, United States\|CTCA - Midwestern Regional Medical Center, Zion, Illinois, 60099, United States\|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States\|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States\|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States\|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, 55404, United States\|Mayo Clinic, Rochester, Minnesota, 55905, United States\|Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, 39401, United States\|Montefiore Einstein Medical Center for Cancer Care, Bronx, New York, 10461, United States\|North Shore Hematology Oncology Associates DBA New York Cancer and Blood Specialists, Bronx, New York, 10469, United States\|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States\|NYU Langone Medical Center, New York, New York, 10016, United States\|Weill Cornell Medical College, New York, New York, 10065, United States\|North Shore Hematology Oncology Associates P.C. DBA NY Cancer and Blood Specialists, Port Jefferson Station, New York, 11776, United States\|Duke University Medical Center, Durham, North Carolina, 27710, United States\|Cleveland Clinic, Cleveland, Ohio, 44195, United States\|The Ohio State University, Columbus, Ohio, 43210, United States\|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, 74146, United States\|CTCA - Eastern Regional Medical Center, Philadelphia, Pennsylvania, 19124, United States\|Baptist Cancer Center, Memphis, Tennessee, 38120, United States\|Texas Oncology- Austin, Austin, Texas, 78745, United States\|MD Anderson Cancer Center, Houston, Texas, 77030, United States\|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States\|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States\|Saint Luc University Hospital, Brussels, Belgium\|University Hospitals Leuven, Leuven, Belgium\|Ambroise Pare University Hospital Center, Mons, Belgium\|General Hospital Delta, Roeselare, Belgium\|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada\|BC Cancer - Vancouver, Vancouver, British Columbia, V5Z 4E6, Canada\|London Regional Cancer Program, London, Ontario, N6A 5W9, Canada\|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada\|Hopital Larrey, CHU Toulouse, Unité d'Oncologie des Voies Respiratoires, Toulouse, France\|Gustave Roussy Oncology Institute, Department of Medical Oncology, Villejuif, France\|Soroka Medical Center, Be'er Sheva, Israel\|Rambam Healthcare Campus, Haifa, Israel\|Hadassah Medical Center, Jerusalem, Israel\|Rabin Medical Center, Petah Tikva, Israel\|National Cancer Institute, IRCCS, Department of Medical Oncology, Milan, Italy\|Santa Maria delle Croci Hospital, Ravenna, Italy\|National Cancer Institute Regina Elena, IRCCS, Operative Unit of Medical Oncology A 1, Rome, Italy\|Erasmus Medical Center, Rotterdam, Netherlands\|University Hospital Germans Trias i Pujol, Department of Medical Oncology, Barcelona, Spain\|University Hospital 12 de Octubre, Madrid, Spain Less <<
NCT03744715	NSCLC\|Breast Cancer	PHASE2	TERMINATED	2023-03-03	Pacific Shores Medical Group, ... More >>Long Beach, California, 90813, United States\|Hattiesburg Clinic Hematology Oncology, Hattiesburg, Mississippi, 39401, United States\|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States\|UPMC, Pittsburgh, Pennsylvania, 15232, United States\|UT MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT02659514	Breast Cancer	PHASE2	COMPLETED	2020-03-11	Clearview Cancer Center, Hunts... More >>ville, Alabama, 35805, United States\|Pacific Cancer Medical Center, Inc., Anaheim, California, 92801, United States\|Marin Cancer Care, Inc, Greenbrae, California, 94904, United States\|Alliance Research Centers, Laguna Hills, California, 92653, United States\|PacificShores Medical Group, Long Beach, California, 90813, United States\|Valley Medical Oncology Consultants, Pleasanton, California, 94588, United States\|Innovative Clinical Research Institute, Whittier, California, 90603, United States\|AMPM Research Clinic, Miami Gardens, Florida, 33169, United States\|FL Cancer Research Institute, Plantation, Florida, 33324, United States\|Bond Clinic, P.A., Winter Haven, Florida, 33880, United States\|Triple Army Medical Cente, Honolulu, Hawaii, 96859, United States\|Franciscan St. Francis Health, Indianapolis, Indiana, 46237, United States\|The University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, 66205, United States\|Hattiesburg Clinic Hematology Oncology, Hattiesburg, Mississippi, 39401, United States\|Washington University, Saint Louis, Missouri, 63110, United States\|St. Vincent Frontier Cancer Center, Billings, Montana, 59102, United States\|North Shore Hematology Oncology Associates, East Setauket, New York, 11733, United States\|Hudson Valley Hematology Oncology Associates, Poughkeepsie, New York, 12601, United States\|White Plain Hospital, White Plains, New York, 10601, United States\|Waverly Hematology Oncology, Cary, North Carolina, 27518, United States\|Aultman Hospital, Canton, Ohio, 44710, United States\|Ohio State University, Columbus, Ohio, 43210, United States\|Oklahoma Cancer Specialists & Research Institute, LLC, Tulsa, Oklahoma, 74146, United States\|Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, 15213, United States\|Charleston Cancer Center, Charleston, South Carolina, 29406, United States\|Carolina Blood and Cancer Care Associates PA, Rock Hill, South Carolina, 29732, United States\|Oncology Consultants, P.A., Houston, Texas, 77030, United States\|SAMMC - Hem/Onc Clinic, Houston, Texas, 78234, United States\|Texas Oncology-McAllen, McAllen, Texas, 78503, United States\|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States\|Scott & White Memorial Hospital, Temple, Texas, 76508, United States\|Providence Regional Cancer System, Lacey, Washington, 98503, United States\|Medical Oncology Associates, PS, Spokane, Washington, 99208, United States\|Northwest Medical Specialties, PLLC, Tacoma, Washington, 98405, United States\|West Virginia University, Morgantown, West Virginia, 26506, United States Less <<
NCT01455571	Advanced Solid Tumor	PHASE1	COMPLETED	2025-01-13	Seoul National University Hosp... More >>ital, Seoul, Korea, Republic of Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.04mL 0.41mL 0.20mL	10.18mL 2.04mL 1.02mL	20.35mL 4.07mL 2.04mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed